Format

Send to

Choose Destination
Oncotarget. 2015 Jun 10;6(16):14584-95.

Proteomic profiling of high risk medulloblastoma reveals functional biology.

Author information

1
Center for Cancer and Immunology Research, Children's National Medical Center, Washington DC, USA.
2
UQ Child Health Research Centre, The University of Queensland and Queensland Children's Medical Research Institute, Children's Health, Queensland, Australia.
3
Division of Pediatric Neurooncology, German Cancer Research Center, Heidleberg, Germany.
4
Sanford-Burnham Medical Research Institute, La Jolla, California, USA.
5
Department of Neurosurgery, Hospital for Sick Children, Toronto, Canada.
6
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
7
Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington DC, USA.
8
Center for Genetic Medicine, Children's National Medical Center, Washington DC, USA.

Abstract

Genomic characterization of medulloblastoma has improved molecular risk classification but struggles to define functional biological processes, particularly for the most aggressive subgroups. We present here a novel proteomic approach to this problem using a reference library of stable isotope labeled medulloblastoma-specific proteins as a spike-in standard for accurate quantification of the tumor proteome. Utilizing high-resolution mass spectrometry, we quantified the tumor proteome of group 3 medulloblastoma cells and demonstrate that high-risk MYC amplified tumors can be segregated based on protein expression patterns. We cross-validated the differentially expressed protein candidates using an independent transcriptomic data set and further confirmed them in a separate cohort of medulloblastoma tissue samples to identify the most robust proteogenomic differences. Interestingly, highly expressed proteins associated with MYC-amplified tumors were significantly related to glycolytic metabolic pathways via alternative splicing of pyruvate kinase (PKM) by heterogeneous ribonucleoproteins (HNRNPs). Furthermore, when maintained under hypoxic conditions, these MYC-amplified tumors demonstrated increased viability compared to non-amplified tumors within the same subgroup. Taken together, these findings highlight the power of proteomics as an integrative platform to help prioritize genetic and molecular drivers of cancer biology and behavior.

KEYWORDS:

cMYC; cancer; glycolysis; medulloblastoma; proteomics

PMID:
25970789
PMCID:
PMC4546489
DOI:
10.18632/oncotarget.3927
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center